Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of FPP003 in axial spondyloarthritis
jRCT2050230093Phase 2Completed
- Sponsor
- Not applicable
- Start
- Sep 2023
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FPP003 in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Not applicable. Primary endpoints: Safety endpoint and Immunogenicity endpoint. Started Sep 2023; status: completed.
02
Drugs
FPP003
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on jRCT2050230093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2050230093.